Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
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Supplemental Table I 
Supplemental File 1. MammaPrint and IntClust classifications.
In breast cancer, the MammaPrint test can classify patients into two risk groups, low or high risk of metastasis (van 't Veer et al., 2002) . For 17 paired samples with MammaPrint results, most had the same classification between pre-and post-treatment samples (7 remained Low-Risk and 7 remained High-Risk). Three samples however, did change in result (2 samples from Low-to High-Risk during treatment and 1 sample changed from High-to Low-Risk.) (Supplemental Figure 1A ). An additional classification method that uses both gene expression and DNA copy number data also classifies breast cancer samples into 10 different groups associated distinct 
